FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Virol / Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling i...
Journal of virology2016; 90(23); 10670-10681; doi: 10.1128/JVI.01634-16

Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission.

Abstract: Multiple novel members of the genus Hepacivirus have recently been discovered in diverse mammalian species. However, to date, their replication mechanisms and zoonotic potential have not been explored in detail. The NS3/4A serine protease of hepatitis C virus (HCV) is critical for cleavage of the viral polyprotein. It also cleaves the cellular innate immune adaptor MAVS, thus decreasing interferon (IFN) production and contributing to HCV persistence in the human host. To investigate the conservation of fundamental aspects of the hepaciviral life cycle, we explored if MAVS cleavage and suppression of innate immune signaling represent a common mechanism employed across different clades of the genus Hepacivirus to enhance viral replication. To estimate the zoonotic potential of these nonhuman hepaciviruses, we assessed if their NS3/4A proteases were capable of cleaving human MAVS. NS3/4A proteases of viruses infecting colobus monkeys, rodents, horses, and cows cleaved the MAVS proteins of their cognate hosts and interfered with the ability of MAVS to induce the IFN-β promoter. All NS3/4A proteases from nonhuman viruses readily cleaved human MAVS. Thus, NS3/4A-dependent cleavage of MAVS is a conserved replication strategy across multiple clades within the genus Hepacivirus Human MAVS is susceptible to cleavage by these nonhuman viral proteases, indicating that it does not pose a barrier for zoonotic transmission of these viruses to humans. Objective: Virus infection is recognized by cellular sensor proteins triggering innate immune signaling and antiviral defenses. While viruses have evolved strategies to thwart these antiviral programs in their cognate host species, these evasion mechanisms are often ineffective in a novel host, thus limiting viral transmission across species. HCV, the best-characterized member of the genus Hepacivirus within the family Flaviviridae, uses its NS3/4A protease to disrupt innate immune signaling by cleaving the cellular adaptor protein MAVS. Recently, a large number of HCV-related viruses have been discovered in various animal species, including wild, livestock, and companion animals. We show that the NS3/4A proteases of these hepaciviruses from different animals and representing various clades of the genus cleave their cognate host MAVS proteins in addition to human MAVS. Therefore, cleavage of MAVS is a common strategy of hepaciviruses, and human MAVS is likely unable to limit replication of these nonhuman viruses upon zoonotic exposure.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Get Full Text
Publication Date: 2016-11-14 PubMed ID: 27654291PubMed Central: PMC5110154DOI: 10.1128/JVI.01634-16Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research focuses on studying how various Hepaciviruses interfere with MAVS signaling, an essential part of the immune response, in both their animal hosts and humans, which in turn implicates their possible zoonotic transmission.

Study Objective and Importance

  • The ultimate goal of the research is to explore the replication mechanisms of Hepaciviruses and delve into their potential for zoonotic transmission – i.e., their ability to jump from their initial animal hosts to humans.
  • This research is essential since Hepaciviruses, specifically hepatitis C virus (HCV), interfere with the immune response of hosts, leading to persistence of the virus potentially causing long-term health issues.

Hepacivirus Mechanisms

  • HCV, utilizes a protease known as NS3/4A to disrupt immune signaling by cleaving a cellular protein called MAVS, which is critical for antiviral defenses.
  • A multitude of HCV-related viruses have recently been found in various animals, such as rodents, horses, and cows. This research focused on the application of the same MAVS cleavage by the NS3/4A proteases in these HCV-related viruses.

Key Findings

  • The NS3/4A proteases from these hepaciviruses displayed the ability to cleave MAVS proteins of both their originating animal species and humans, showing that this method of immune disruption is a common strategy among these viruses.
  • The findings suggest that human MAVS is susceptible to interference by these nonhuman viral proteases. That means it does not pose a barrier to these viruses’ zoonotic transmission, allowing for the potential infection of humans.

Implications

  • This research suggests that the nonhuman Hepaciviruses have the potential to bypass the human body’s immune defenses, allowing for their replication in a new host.
  • Understanding this mechanism brings forth new knowledge in combating viral diseases, providing a deeper insight into virus-host interactions and presenting better strategies for preventing or treating Hepacivirus infections.

Cite This Article

APA
Anggakusuma , Brown RJP, Banda DH, Todt D, Vieyres G, Steinmann E, Pietschmann T. (2016). Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmission. J Virol, 90(23), 10670-10681. https://doi.org/10.1128/JVI.01634-16

Publication

Journal of virology
ISSN: 1098-5514
NlmUniqueID: 0113724
Country: United States
Language: English
Volume: 90
Issue: 23
Pages: 10670-10681

Researcher Affiliations

Anggakusuma,
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Brown, Richard J P
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Banda, Dominic H
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Todt, Daniel
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Vieyres, Gabrielle
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Steinmann, Eike
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany.
Pietschmann, Thomas
  • Institute for Experimental Virology, Centre for Experimental and Clinical Infection Research, TWINCORE, Hanover, Germany thomas.pietschmann@twincore.de.

MeSH Terms

  • Adaptor Proteins, Signal Transducing / genetics
  • Adaptor Proteins, Signal Transducing / immunology
  • Adaptor Proteins, Signal Transducing / physiology
  • Amino Acid Motifs
  • Amino Acid Sequence
  • Animals
  • Conserved Sequence
  • Evolution, Molecular
  • Genetic Variation
  • Hepacivirus / enzymology
  • Hepacivirus / immunology
  • Hepacivirus / pathogenicity
  • Hepatitis C / immunology
  • Hepatitis C / transmission
  • Hepatitis C / virology
  • Host Specificity
  • Humans
  • Immunity, Innate
  • Serine Proteases / genetics
  • Serine Proteases / physiology
  • Signal Transduction
  • Viral Nonstructural Proteins / genetics
  • Viral Nonstructural Proteins / physiology
  • Virus Replication / immunology
  • Zoonoses / immunology
  • Zoonoses / transmission
  • Zoonoses / virology

References

This article includes 41 references
  1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases.. Nature 2008 Feb 21;451(7181):990-3.
    doi: 10.1038/nature06536pmc: PMC5960580pubmed: 18288193google scholar: lookup
  2. Woolhouse ME, Haydon DT, Antia R. Emerging pathogens: the epidemiology and evolution of species jumps.. Trends Ecol Evol 2005 May;20(5):238-44.
    doi: 10.1016/j.tree.2005.02.009pmc: PMC7119200pubmed: 16701375google scholar: lookup
  3. . Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.. Lancet 2015 Aug 22;386(9995):743-800.
    doi: 10.1016/S0140-6736(15)60692-4pmc: PMC4561509pubmed: 26063472google scholar: lookup
  4. Ding Q, von Schaewen M, Ploss A. The impact of hepatitis C virus entry on viral tropism.. Cell Host Microbe 2014 Nov 12;16(5):562-8.
    doi: 10.1016/j.chom.2014.10.009pmc: PMC4272444pubmed: 25525789google scholar: lookup
  5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.. Science 1989 Apr 21;244(4902):359-62.
    doi: 10.1126/science.2523562pubmed: 2523562google scholar: lookup
  6. Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae.. J Gen Virol 2011 Feb;92(Pt 2):233-46.
    doi: 10.1099/vir.0.027490-0pmc: PMC3081076pubmed: 21084497google scholar: lookup
  7. Kapoor A, Simmonds P, Scheel TK, Hjelle B, Cullen JM, Burbelo PD, Chauhan LV, Duraisamy R, Sanchez Leon M, Jain K, Vandegrift KJ, Calisher CH, Rice CM, Lipkin WI. Identification of rodent homologs of hepatitis C virus and pegiviruses.. mBio 2013 Apr 9;4(2):e00216-13.
    doi: 10.1128/mBio.00216-13pmc: PMC3622934pubmed: 23572554google scholar: lookup
  8. Quan PL, Firth C, Conte JM, Williams SH, Zambrana-Torrelio CM, Anthony SJ, Ellison JA, Gilbert AT, Kuzmin IV, Niezgoda M, Osinubi MO, Recuenco S, Markotter W, Breiman RF, Kalemba L, Malekani J, Lindblade KA, Rostal MK, Ojeda-Flores R, Suzan G, Davis LB, Blau DM, Ogunkoya AB, Alvarez Castillo DA, Moran D, Ngam S, Akaibe D, Agwanda B, Briese T, Epstein JH, Daszak P, Rupprecht CE, Holmes EC, Lipkin WI. Bats are a major natural reservoir for hepaciviruses and pegiviruses.. Proc Natl Acad Sci U S A 2013 May 14;110(20):8194-9.
    doi: 10.1073/pnas.1303037110pmc: PMC3657805pubmed: 23610427google scholar: lookup
  9. Baechlein C, Fischer N, Grundhoff A, Alawi M, Indenbirken D, Postel A, Baron AL, Offinger J, Becker K, Beineke A, Rehage J, Becher P. Identification of a Novel Hepacivirus in Domestic Cattle from Germany.. J Virol 2015 Jul;89(14):7007-15.
    doi: 10.1128/JVI.00534-15pmc: PMC4473572pubmed: 25926652google scholar: lookup
  10. Burbelo PD, Dubovi EJ, Simmonds P, Medina JL, Henriquez JA, Mishra N, Wagner J, Tokarz R, Cullen JM, Iadarola MJ, Rice CM, Lipkin WI, Kapoor A. Serology-enabled discovery of genetically diverse hepaciviruses in a new host.. J Virol 2012 Jun;86(11):6171-8.
    doi: 10.1128/JVI.00250-12pmc: PMC3372197pubmed: 22491452google scholar: lookup
  11. Corman VM, Grundhoff A, Baechlein C, Fischer N, Gmyl A, Wollny R, Dei D, Ritz D, Binger T, Adankwah E, Marfo KS, Annison L, Annan A, Adu-Sarkodie Y, Oppong S, Becher P, Drosten C, Drexler JF. Highly divergent hepaciviruses from African cattle.. J Virol 2015 Jun;89(11):5876-82.
    doi: 10.1128/JVI.00393-15pmc: PMC4442428pubmed: 25787289google scholar: lookup
  12. Kapoor A, Simmonds P, Gerold G, Qaisar N, Jain K, Henriquez JA, Firth C, Hirschberg DL, Rice CM, Shields S, Lipkin WI. Characterization of a canine homolog of hepatitis C virus.. Proc Natl Acad Sci U S A 2011 Jul 12;108(28):11608-13.
    doi: 10.1073/pnas.1101794108pmc: PMC3136326pubmed: 21610165google scholar: lookup
  13. Lauck M, Sibley SD, Lara J, Purdy MA, Khudyakov Y, Hyeroba D, Tumukunde A, Weny G, Switzer WM, Chapman CA, Hughes AL, Friedrich TC, O'Connor DH, Goldberg TL. A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old World primate.. J Virol 2013 Aug;87(16):8971-81.
    doi: 10.1128/JVI.00888-13pmc: PMC3754081pubmed: 23740998google scholar: lookup
  14. Berg MG, Lee D, Coller K, Frankel M, Aronsohn A, Cheng K, Forberg K, Marcinkus M, Naccache SN, Dawson G, Brennan C, Jensen DM, Hackett J Jr, Chiu CY. Discovery of a Novel Human Pegivirus in Blood Associated with Hepatitis C Virus Co-Infection.. PLoS Pathog 2015 Dec;11(12):e1005325.
    doi: 10.1371/journal.ppat.1005325pmc: PMC4676677pubmed: 26658760google scholar: lookup
  15. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected?. Emerg Microbes Infect 2012 Dec;1(12):e46.
    doi: 10.1038/emi.2012.47pmc: PMC3630908pubmed: 26038413google scholar: lookup
  16. Mandl JN, Ahmed R, Barreiro LB, Daszak P, Epstein JH, Virgin HW, Feinberg MB. Reservoir host immune responses to emerging zoonotic viruses.. Cell 2015 Jan 15;160(1-2):20-35.
    doi: 10.1016/j.cell.2014.12.003pmc: PMC4390999pubmed: 25533784google scholar: lookup
  17. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus.. Nature 2005 Oct 20;437(7062):1167-72.
    doi: 10.1038/nature04193pubmed: 16177806google scholar: lookup
  18. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.. Proc Natl Acad Sci U S A 2005 Feb 22;102(8):2992-7.
    doi: 10.1073/pnas.0408824102pmc: PMC548795pubmed: 15710891google scholar: lookup
  19. Patel MR, Loo YM, Horner SM, Gale M Jr, Malik HS. Convergent evolution of escape from hepaciviral antagonism in primates.. PLoS Biol 2012;10(3):e1001282.
    doi: 10.1371/journal.pbio.1001282pmc: PMC3302847pubmed: 22427742google scholar: lookup
  20. Scull MA, Shi C, de Jong YP, Gerold G, Ries M, von Schaewen M, Donovan BM, Labitt RN, Horwitz JA, Gaska JM, Hrebikova G, Xiao JW, Flatley B, Fung C, Chiriboga L, Walker CM, Evans DT, Rice CM, Ploss A. Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.. Hepatology 2015 Jul;62(1):57-67.
    doi: 10.1002/hep.27773pmc: PMC4482775pubmed: 25820364google scholar: lookup
  21. Parera M, Martrus G, Franco S, Clotet B, Martinez MA. Canine hepacivirus NS3 serine protease can cleave the human adaptor proteins MAVS and TRIF.. PLoS One 2012;7(8):e42481.
    doi: 10.1371/journal.pone.0042481pmc: PMC3411667pubmed: 22870331google scholar: lookup
  22. Scheel TK, Kapoor A, Nishiuchi E, Brock KV, Yu Y, Andrus L, Gu M, Renshaw RW, Dubovi EJ, McDonough SP, Van de Walle GR, Lipkin WI, Divers TJ, Tennant BC, Rice CM. Characterization of nonprimate hepacivirus and construction of a functional molecular clone.. Proc Natl Acad Sci U S A 2015 Feb 17;112(7):2192-7.
    doi: 10.1073/pnas.1500265112pmc: PMC4343093pubmed: 25646476google scholar: lookup
  23. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.. Mol Biol Evol 2011 Oct;28(10):2731-9.
    doi: 10.1093/molbev/msr121pmc: PMC3203626pubmed: 21546353google scholar: lookup
  24. Anggakusuma, Frentzen A, Gürlevik E, Yuan Q, Steinmann E, Ott M, Staeheli P, Schmid-Burgk J, Schmidt T, Hornung V, Kuehnel F, Pietschmann T. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons.. J Virol 2015 Apr;89(7):3833-45.
    doi: 10.1128/JVI.03129-14pmc: PMC4403415pubmed: 25609814google scholar: lookup
  25. Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.. PLoS Pathog 2010 Jul 1;6(7):e1000978.
    doi: 10.1371/journal.ppat.1000978pmc: PMC2895659pubmed: 20617177google scholar: lookup
  26. Pfaender S, Cavalleri JM, Walter S, Doerrbecker J, Campana B, Brown RJ, Burbelo PD, Postel A, Hahn K, Anggakusuma, Riebesehl N, Baumgärtner W, Becher P, Heim MH, Pietschmann T, Feige K, Steinmann E. Clinical course of infection and viral tissue tropism of hepatitis C virus-like nonprimate hepaciviruses in horses.. Hepatology 2015 Feb;61(2):447-59.
    doi: 10.1002/hep.27440pubmed: 25212983google scholar: lookup
  27. Drexler JF, Corman VM, Müller MA, Lukashev AN, Gmyl A, Coutard B, Adam A, Ritz D, Leijten LM, van Riel D, Kallies R, Klose SM, Gloza-Rausch F, Binger T, Annan A, Adu-Sarkodie Y, Oppong S, Bourgarel M, Rupp D, Hoffmann B, Schlegel M, Kümmerer BM, Krüger DH, Schmidt-Chanasit J, Setién AA, Cottontail VM, Hemachudha T, Wacharapluesadee S, Osterrieder K, Bartenschlager R, Matthee S, Beer M, Kuiken T, Reusken C, Leroy EM, Ulrich RG, Drosten C. Evidence for novel hepaciviruses in rodents.. PLoS Pathog 2013;9(6):e1003438.
    doi: 10.1371/journal.ppat.1003438pmc: PMC3688547pubmed: 23818848google scholar: lookup
  28. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3.. Cell 2005 Sep 9;122(5):669-82.
    doi: 10.1016/j.cell.2005.08.012pubmed: 16125763google scholar: lookup
  29. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.. Proc Natl Acad Sci U S A 2005 Dec 6;102(49):17717-22.
    doi: 10.1073/pnas.0508531102pmc: PMC1308909pubmed: 16301520google scholar: lookup
  30. Bartenschlager R. The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy.. J Viral Hepat 1999 May;6(3):165-81.
    doi: 10.1046/j.1365-2893.1999.00152.xpubmed: 10607229google scholar: lookup
  31. Grakoui A, McCourt DW, Wychowski C, Feinstone SM, Rice CM. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites.. J Virol 1993 May;67(5):2832-43.
    pmc: PMC237608pubmed: 8386278doi: 10.1128/JVI.67.5.2832-2843.1993google scholar: lookup
  32. Rögnvaldsson T, Etchells TA, You L, Garwicz D, Jarman I, Lisboa PJ. How to find simple and accurate rules for viral protease cleavage specificities.. BMC Bioinformatics 2009 May 16;10:149.
    doi: 10.1186/1471-2105-10-149pmc: PMC2698905pubmed: 19445713google scholar: lookup
  33. Jones CT, Catanese MT, Law LM, Khetani SR, Syder AJ, Ploss A, Oh TS, Schoggins JW, MacDonald MR, Bhatia SN, Rice CM. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system.. Nat Biotechnol 2010 Feb;28(2):167-71.
    doi: 10.1038/nbt.1604pmc: PMC2828266pubmed: 20118917google scholar: lookup
  34. Pybus OG, Thézé J. Hepacivirus cross-species transmission and the origins of the hepatitis C virus.. Curr Opin Virol 2016 Feb;16:1-7.
    doi: 10.1016/j.coviro.2015.10.002pubmed: 26517843google scholar: lookup
  35. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM, Gale M Jr. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.. Proc Natl Acad Sci U S A 2006 Apr 11;103(15):6001-6.
    doi: 10.1073/pnas.0601523103pmc: PMC1458687pubmed: 16585524google scholar: lookup
  36. Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M, Gerold G, Labitt RN, Rice CM, Ploss A. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines.. Virology 2013 Sep;444(1-2):1-11.
    doi: 10.1016/j.virol.2013.05.036pmc: PMC3755106pubmed: 23777661google scholar: lookup
  37. Dansako H, Ikeda M, Kato N. Limited suppression of the interferon-beta production by hepatitis C virus serine protease in cultured human hepatocytes.. FEBS J 2007 Aug;274(16):4161-76.
    doi: 10.1111/j.1742-4658.2007.05942.xpubmed: 17651439google scholar: lookup
  38. Brenndörfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG. Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.. Hepatology 2009 Jun;49(6):1810-20.
    doi: 10.1002/hep.22857pubmed: 19475692google scholar: lookup
  39. Kang X, Chen X, He Y, Guo D, Guo L, Zhong J, Shu HB. DDB1 is a cellular substrate of NS3/4A protease and required for hepatitis C virus replication.. Virology 2013 Jan 20;435(2):385-94.
    doi: 10.1016/j.virol.2012.10.025pubmed: 23137809google scholar: lookup
  40. Morikawa K, Gouttenoire J, Hernandez C, Dao Thi VL, Tran HT, Lange CM, Dill MT, Heim MH, Donzé O, Penin F, Quadroni M, Moradpour D. Quantitative proteomics identifies the membrane-associated peroxidase GPx8 as a cellular substrate of the hepatitis C virus NS3-4A protease.. Hepatology 2014 Feb;59(2):423-33.
    doi: 10.1002/hep.26671pubmed: 23929719google scholar: lookup
  41. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells.. Nature 2009 Feb 12;457(7231):882-6.
    doi: 10.1038/nature07684pmc: PMC2762424pubmed: 19182773google scholar: lookup

Citations

This article has been cited 19 times.
  1. Breitfeld J, Fischer N, Tsachev I, Marutsov P, Baymakova M, Plhal R, Keuling O, Becher P, Baechlein C. Expanded Diversity and Host Range of Bovine Hepacivirus-Genomic and Serological Evidence in Domestic and Wild Ruminant Species.. Viruses 2022 Jun 30;14(7).
    doi: 10.3390/v14071457pubmed: 35891438google scholar: lookup
  2. de Martinis C, Cardillo L, Esposito C, Viscardi M, Barca L, Cavallo S, D'Alessio N, Martella V, Fusco G. First identification of bovine hepacivirus in wild boars.. Sci Rep 2022 Jul 8;12(1):11678.
    doi: 10.1038/s41598-022-15928-7pubmed: 35804025google scholar: lookup
  3. Yin M, Wen W, Wang H, Zhao Q, Zhu H, Chen H, Li X, Qian P. Porcine Sapelovirus 3C(pro) Inhibits the Production of Type I Interferon.. Front Cell Infect Microbiol 2022;12:852473.
    doi: 10.3389/fcimb.2022.852473pubmed: 35782136google scholar: lookup
  4. Burkard T, Proske N, Resner K, Collignon L, Knegendorf L, Friesland M, Verhoye L, Sayed IM, Brüggemann Y, Nocke MK, Behrendt P, Wedemeyer H, Meuleman P, Todt D, Steinmann E. Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems.. Cells 2022 Mar 8;11(6).
    doi: 10.3390/cells11060927pubmed: 35326378google scholar: lookup
  5. Tsu BV, Fay EJ, Nguyen KT, Corley MR, Hosuru B, Dominguez VA, Daugherty MD. Running With Scissors: Evolutionary Conflicts Between Viral Proteases and the Host Immune System.. Front Immunol 2021;12:769543.
    doi: 10.3389/fimmu.2021.769543pubmed: 34790204google scholar: lookup
  6. Sims S, Michaelsen K, Burkhard S, Fraefel C. In Vitro Comparison of the Internal Ribosomal Entry Site Activity from Rodent Hepacivirus and Pegivirus and Construction of Pseudoparticles.. Adv Virol 2021;2021:5569844.
    doi: 10.1155/2021/5569844pubmed: 34422054google scholar: lookup
  7. Dabrowska A, Milewska A, Ner-Kluza J, Suder P, Pyrc K. Mass Spectrometry versus Conventional Techniques of Protein Detection: Zika Virus NS3 Protease Activity towards Cellular Proteins.. Molecules 2021 Jun 18;26(12).
    doi: 10.3390/molecules26123732pubmed: 34207340google scholar: lookup
  8. Moreira-Soto A, Arroyo-Murillo F, Sander AL, Rasche A, Corman V, Tegtmeyer B, Steinmann E, Corrales-Aguilar E, Wieseke N, Avey-Arroyo J, Drexler JF. Cross-order host switches of hepatitis C-related viruses illustrated by a novel hepacivirus from sloths.. Virus Evol 2020 Jul;6(2):veaa033.
    doi: 10.1093/ve/veaa033pubmed: 32704383google scholar: lookup
  9. Tran HTL, Morikawa K, Anggakusuma, Zibi R, Thi VLD, Penin F, Heim MH, Quadroni M, Pietschmann T, Gouttenoire J, Moradpour D. OCIAD1 is a host mitochondrial substrate of the hepatitis C virus NS3-4A protease.. PLoS One 2020;15(7):e0236447.
    doi: 10.1371/journal.pone.0236447pubmed: 32697788google scholar: lookup
  10. B UR, Tandon H, Pradhan MK, Adhikesavan H, Srinivasan N, Das S, Jayaraman N. Potent HCV NS3 Protease Inhibition by a Water-Soluble Phyllanthin Congener.. ACS Omega 2020 May 26;5(20):11553-11562.
    doi: 10.1021/acsomega.0c00786pubmed: 32478245google scholar: lookup
  11. Ploss A, Kapoor A. Animal Models of Hepatitis C Virus Infection.. Cold Spring Harb Perspect Med 2020 May 1;10(5).
    doi: 10.1101/cshperspect.a036970pubmed: 31843875google scholar: lookup
  12. Wolfisberg R, Holmbeck K, Nielsen L, Kapoor A, Rice CM, Bukh J, Scheel TKH. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.. J Virol 2019 Oct 1;93(19).
    doi: 10.1128/JVI.00733-19pubmed: 31292246google scholar: lookup
  13. Rasche A, Sander AL, Corman VM, Drexler JF. Evolutionary biology of human hepatitis viruses.. J Hepatol 2019 Mar;70(3):501-520.
    doi: 10.1016/j.jhep.2018.11.010pubmed: 30472320google scholar: lookup
  14. Ramsay JD, Evanoff R, Mealey RH. Hepacivirus A Infection in Horses Defines Distinct Envelope Hypervariable Regions and Elucidates Potential Roles of Viral Strain and Adaptive Immune Status in Determining Envelope Diversity and Infection Outcome.. J Virol 2018 Sep 15;92(18).
    doi: 10.1128/JVI.00314-18pubmed: 29976666google scholar: lookup
  15. Boukadida C, Fritz M, Blumen B, Fogeron ML, Penin F, Martin A. NS2 proteases from hepatitis C virus and related hepaciviruses share composite active sites and previously unrecognized intrinsic proteolytic activities.. PLoS Pathog 2018 Feb;14(2):e1006863.
    doi: 10.1371/journal.ppat.1006863pubmed: 29415072google scholar: lookup
  16. Tanaka T, Otoguro T, Yamashita A, Kasai H, Fukuhara T, Matsuura Y, Moriishi K. Roles of the 5' Untranslated Region of Nonprimate Hepacivirus in Translation Initiation and Viral Replication.. J Virol 2018 Apr 1;92(7).
    doi: 10.1128/JVI.01997-17pubmed: 29343570google scholar: lookup
  17. Lei J, Hilgenfeld R. RNA-virus proteases counteracting host innate immunity.. FEBS Lett 2017 Oct;591(20):3190-3210.
    doi: 10.1002/1873-3468.12827pubmed: 28850669google scholar: lookup
  18. Pfaender S, Walter S, Grabski E, Todt D, Bruening J, Romero-Brey I, Gather T, Brown RJ, Hahn K, Puff C, Pfankuche VM, Hansmann F, Postel A, Becher P, Thiel V, Kalinke U, Wagner B, Bartenschlager R, Baumgärtner W, Feige K, Pietschmann T, Cavalleri JM, Steinmann E. Immune protection against reinfection with nonprimate hepacivirus.. Proc Natl Acad Sci U S A 2017 Mar 21;114(12):E2430-E2439.
    doi: 10.1073/pnas.1619380114pubmed: 28275093google scholar: lookup
  19. Bruening J, Weigel B, Gerold G. The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy.. J Immunol Res 2017;2017:7232361.
    doi: 10.1155/2017/7232361pubmed: 28255563google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.